Reconstitute in ddH2O. Store at -20ºC.
Purity was assessed by SDS-PAGE (≥90%) and by HPLC (≥90%).
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
InterferonLambda 1, IFN-Lambda 1, IFNLambda1, IFNLambda 1, ZCYTO21, Interleukin29, Interferon-Lambda 1, IL29, InterferonLambda1, Interleukin-29, IL-29, Cytokine ZCYTO21, IFNL1, IL 29, IFN Lambda 1, Interleukin 29, Interferon Lambda 1
IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor beta (IL10RB) and interleukin 28 receptor alpha . IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues. Recombinant human IL-29 produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of?20 kDa.